Effect of Bupropion versus placebo on the management of fatigue caused by multiple sclerosis

Effect of Bupropion versus placebo on the management of fatigue caused by multiple sclerosis: a double-blind randomized clinical trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20120215009014N465

Enrollment

Registered

2023-03-09

Start date

2023-04-21

Completion date

Unknown

Last updated

2023-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple sclerosis. Multiple sclerosis

Interventions

Intervention 1: Intervention group: Routine Treatment plus Bupropion tablet 75 mg daily for 3 days then twice a day for 60 days. Intervention 2: Control group: Routine Treatment plus placebo tablet (s

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Age 18 to 65 years Multiple sclerosis

Exclusion criteria

Exclusion criteria: Pregnancy or breastfeeding Hepatic or renal failure A history of convulsion or epilepsy A history of alcohol use A history of attempting suicide

Design outcomes

Primary

Measure	Time frame
Fatigue score. Timepoint: Before the intervention and one and two months after the intervention. Method of measurement: Using the Modified Fatigue Impact Scale (MFIS).;Quality of life score. Timepoint: Before Intervention and two months after the intervention. Method of measurement: Using Multiple Sclerosis Quality of Life-54 Questionnaire (MSQOL-54).;Disability score. Timepoint: Before the intervention and one and two months after the intervention. Method of measurement: using the Expanded Disability Status Scale (EDSS).	—

Measure

Time frame

Fatigue score. Timepoint: Before the intervention and one and two months after the intervention. Method of measurement: Using the Modified Fatigue Impact Scale (MFIS).;Quality of life score. Timepoint: Before Intervention and two months after the intervention. Method of measurement: Using Multiple Sclerosis Quality of Life-54 Questionnaire (MSQOL-54).;Disability score. Timepoint: Before the intervention and one and two months after the intervention. Method of measurement: using the Expanded Disability Status Scale (EDSS).

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactShiva Tane

Hamedan University of Medical Sciences

shivatnh3a@gmail.com+98 81 3838 0572

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026